133647-95-7

Basic information

• Product Name: methyl (1R,2S,3S,5S)-3-(4-iodophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
• Synonyms: 2-Carbomethoxy-3-(4-iodophenyl)tropane;3-(4-Iodophenyl)tropane-2-carboxylic acid methyl ester;C069723;I(123)beta-Cit;Iodine (125)-rti-55;methyl (1R,2S,3S,5S)-3-(4-iodophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate;RTI 55;RTI-5
• CAS NO: 133647-95-7
• Molecular Formula: C16H20INO2
• Molecular Weight: 385.23997
• Product Categories: pharmaceutical intermdediate
• Mol File: 133647-95-7.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 405.3°Cat760mmHg
• Flash Point: 198.9°C
• Appearance: /
• Density: 1.493g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.589
• CAS DataBase Reference: methyl (1R,2S,3S,5S)-3-(4-iodophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (1R,2S,3S,5S)-3-(4-iodophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate(133647-95-7)
• EPA Substance Registry System: methyl (1R,2S,3S,5S)-3-(4-iodophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate(133647-95-7)

Safety Data

• Hazardous Substances Data: 133647-95-7(Hazardous Substances Data)

Usage

General Description

Methyl (1R,2S,3S,5S)-3-(4-iodophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate is a complex organic compound with a molecular structure that includes a bicyclic ring system and a carboxylate functional group. It also contains a methyl group, an iodophenyl group, and a nitrogen atom. methyl (1R,2S,3S,5S)-3-(4-iodophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate belongs to the class of esters and is commonly used in organic synthesis and pharmaceutical research. Its unique structure and functional groups make it a potentially important building block for the production of new drugs and materials. Additionally, its stereochemistry and bicyclic ring system could potentially contribute to specific biological activities, making it an important target for further chemical and pharmacological studies.

InChI:InChI=1/C16H20INO2/c1-18-12-7-8-14(18)15(16(19)20-2)13(9-12)10-3-5-11(17)6-4-10/h3-6,12-15H,7-9H2,1-2H3/t12-,13+,14+,15-/m0/s1

Upstream product

• 50373-10-9 methyl ecgonidine 
• 50583-05-6 Win 35065-3 
• 184376-56-5 (1R)-3α-phenyltropane-2β-carboxylic acid methyl ester 
• 146726-47-8 (1R)-3α-phenyl-2β-(3-methyl-[1,2,4]oxadiazole-5-yl)tropane 
• 67-56-1 methanol 
• 223384-61-0 3α-(iodophenyl)-2β-(3'-methyl-1',2',4'-oxadiazol-5'-yl)tropane 
• 114448-26-9 lithium (4-iodophenyl) 
• 591-51-5 phenyllithium 
• 149197-42-2 (1S)-2-carbomethoxy-3-tropinone 
• 50373-10-9 (1S)-anhydroecgonine methyl ester 
• 149110-83-8 (1S)-allopseudoecgonine methyl ester 
• 127279-73-6 3β-(4-nitrophenyl)tropane-2β-carboxylic acid methyl ester 
• 50370-54-2 3β-phenyltropane-2β-carboxylic acid methyl ester 
• 50373-10-9 (R)-(-)-anhydroecgonine methyl ester 

Relevant articles and documents

Enantioselectivity of Cocaine Recognition Sites: Binding of (1S)- and (1R)-2β-Carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT) to Monoamine Transporters

-

Isomerization study of aryltropane analogs of cocaine

Isomerization of brain imaging agents aryltropane cocaine analogs have been examined by HPLC under chemical conditions similar to those encountered during radiolabeling.

Fluoralkenyl nortropanes

Provided are compounds of the following formula: wherein R is C2-C6 mono- or multi-unsaturated hydrocarbon having one or more ethylene, acetylene or allene groups, A is 18 or 19, and X is H or halogen. The compounds of the invention bind to dopamine transporter with high affinity and selectivity and are thus useful as diagnostic and therapeutic agents for diseases associated with dopamine transporter dysfunction. The radiolabeled compounds are useful as imaging agents for visualizing the location and density of dopamine transporter by PET imaging.

A direct iodination method with iodine and silver triflate for the synthesis of SPECT and PET imaging agent precursors

A direct iodination method with iodine and silver triflate for the synthesis of SPECT and PET imaging agent precursors has been developed.